Table 7.
As-treated comparison of outcomes between E+P MHT and unexposed subjects
| Outcome | No. of subjects (annualized %) | Unadjusted HR (95% CI) |
Adjusted HR (95% CI)* |
|
|---|---|---|---|---|
| E+P MHT (n=4,712) |
E+P unexposed (n=7,867) |
|||
| Follow-up time in months Mean (range) | 27.8 (5.6–126.9) | 27.2 (2.6–126.9) | NA | NA |
| Acute MI | 0 (0) | 13 (0.07) | - | - |
| CHD Death | 0 (0) | 3 (0.02) | - | - |
| CABG/PTCA | 3 (0.03) | 3 (0.02) | 1.56 (0.31–7.73) | 1.35 (0.26–6.65) |
| Breast cancer | 34 (0.31) | 58 (0.33) | 0.96 (0.63–1.46) | 0.96 (0.63–1.48) |
| Stroke | 30 (0.27) | 95 (0.54) | 0.51 (0.34–0.77) | 0.50 (0.33–0.76) |
| PE | 3 (0.02) | 2 (0.01) | 2.34 (0.39–14.0) | 2.52 (0.42–15.4) |
| DVT | 3 (0.03) | 8 (0.04) | 0.61 (0.16–2.29) | 0.61 (0.16–2.33) |
| Colon cancer | 7 (0.06) | 23 (0.13) | 0.50 (0.21–1.16) | 0.48 (0.21–1.13) |
| Endometrial | 19 (0.17) | 9 (0.05) | 3.45 (1.56–7.63) | 3.74 (1.68–8.33) |
| Any cancer | 265 (2.5) | 327 (1.9) | 1.33 (1.13–1.56) | 1.36 (1.15–1.60) |
| Vertebral and hip fractures | 73 (0.67) | 121 (0.69) | 0.97 (0.73–1.30) | 1.06 (0.79–1.43) |
| Any fracture | 213 (2.0) | 386 (2.3) | 0.89 (0.75–1.05) | 0.92 (0.78–1.09) |
| Death | 88 (0.79) | 316 (1.7) | 0.46 (0.36–0.58) | 0.50 (0.39–0.63) |
| Global index | 555 (5.36) | 1000 (5.87) | 0.90 (0.81–0.99) | 0.94 (0.85–1.04) |
*
Adjusted for age, statin use, aspirin use, hypercholesterolemia, diabetes medication use, hypertension